Kornimate/medical-research-clean huggingface dataset:
single incision plus one port laparoscopic surgery assistant enhanced recovery after surgery on colorectal cancer

Conditions: Colorectal Cancer

Summary: conventional laparoscopic surgery (cls) for colorectal cancer has been demonstrated to be safe and feasible and present minimally invasive benefits including faster recovery, reduced postoperative pain and shorter hospital stay, also acquiring comparable oncologic outcomes with open surgery. to achieve further minimally invasive outcomes, sils plus one port surgery was attempted by some surgeons. preliminary results showed that sils+1 could achieve better minimally invasive benefits than cls while preserving oncologic feasibility. till now, eras has been practiced in colorectal cancer surgery for approximately 20 years. studies have proven that eras is safe and significantly improved the recovery course of patients during perioperative period, meanwhile, the expense could be greatly reduced. based on eras studies protocols and sils+1 trials, investigators tried to combine sils+1 with eras, hopefully to provide patients with more safe, economic, feasible and rapid surgery and perioperative strategies.


Eligibility criteria:
inclusion criteria: * primary tumor diagnosed as adenocarcinoma confirmed pathologically by endoscopic biopsy * ct1-4a, n0-3, m0 at preoperative evaluation according to the ajcc cancer staging manual seventh edition * located in the cecum, ascending colon, transverse colon, descending colon, sigmoid colon, the upper segment of the rectum. * diameter ≦ 5cm * no severe organ dysfunction * performance status of 0 or 1 on ecog (eastern cooperative oncology group) scale * asa (american society of anesthesiology) score class i or ii * written informed consent exclusion criteria: * unsuitable for patients undergoing single incision plus one port laparoscopic surgery * patients with complications caused by colorectal cancer ( bleeding , perforation, obstruction or incomplete obstruction ) * previous abdominal surgery * malignant diseases within the past 5years * requirements of simultaneous surgery for another diseases

Keywords: colorectal cancer eras single incision plus one laparoscopic surgery
non-interventional study on team conditioning in patients with lymphoma (team)

Conditions: Lymphoma

Summary: lymphoma is a malignant blood disease sensitive to chemotherapy. in case of relapse after first-line treatment, high-dose chemotherapy conditioning followed by autologous hematopoietic stem cell transplantation (auto-hsct) improves patient survival and reduces the risk of relapse. auto-hsct may also be indicated in the first line in case of aggressive lymphoma at high risk of relapse. beam (carmustine, etoposide, aracytine and melphalan) is the more frequently used high-dose conditioning regimen. nevertheless, carmustine is no longer available in europe. the investigators have therefore chosen to replace carmustine by thiotepa and use the team regimen as the new conditioning. indeed, thiotepa is approved by french national agency for the security of drugs (ansm) for use as part of auto-hsct conditioning regimen. the results of team regimen in terms of efficacy and toxicity appear similar to those of beam. however, no study have been performed prospectively. only small series and case reports have been reported. if the study confirms the results of retrospective studies, conditioning by team could become a new standard in auto-hsct for the treatment of lymphoma. this study is non-interventional, prospective with 3 centers. all included patients will receive, according to standard practice and drug label in france, the following diagram: 1. conditioning: * thiotepa 8 mg / kg to j-6 * etoposide 100 mg / m² / 12 h for 4 days (j-5 to d-2) * aracytine 200 mg / m² / 12 h for 4 days (j-5 to d-2) * melphalan 140 mg / m² on day-1 2. transfusion graft: the day d0 with autologous peripheral stem cell transplant 3. care supports: patients will be treated according to the usual procedures of centers participating in the study at the discretion of the investigator. 4. follow-up of patients will not be changed by the study. the main objective of the study is to evaluate the progression-free survival (pfs) of lymphoma patients treated with autologous stem cells after conditioning by team secondary objectives are: * to evaluate overall survival; * to assess the response to treatment; * to evaluate the incidence of relapse; * to assess the toxic transplant related mortality; * to study transplant-related morbidity (infections, nutritional and gastrointestinal toxicity, immune reconstitution).


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 65 years, * lymphoma confirmed by biopsy * first autologous haematopoietic stem cells transplantation after team conditioning exclusion criteria: * vih, hbv, and/or hcv seropositive * contraindication to autologous stem cell transplantation

Keywords: lymphoma team conditioning autologous stem cells transplantation
lifevest trends validation protocol

Conditions: Heart Failure

Summary: this study will evaluate the accuracy of data on body position, daily activity, heart rate, 6-minute walk test, and a health survey collected by the wearable cardioverter defibrillator (wcd).

this is a multi-center validation study of heart failure patients wearing the lifevest wcd modified to collect data on body position, activity, heart rate, 6-minute walk test, and a health survey in order to evaluate data accuracy and patient interactions with the device.

Eligibility criteria:
inclusion criteria: * symptomatic heart failure (i.e., new york heart association (nyha) class ii or higher) * evidence of a prior myocardial infarction (mi) or dilated cardiomyopathy * ejection fraction of 35% or less at the start of wcd use * anticipated to need a wcd for three months or more * at least 18 years of age (over the legal age of providing consent) exclusion criteria: * use of an implantable cardioverter defibrillator (icd), recent removal of an icd, or planned use of an icd within the next three months * need for an assistive device for ambulation (wheelchair, walker, or cane) * use of a unipolar pacemaker * physical or mental conditions that prevent interaction with or wearing of the device * advanced directive prohibiting resuscitation * pregnancy

Keywords: heart failure six minute walk test
the long-term benefit of hydrogel spacer in reducing rectal radiation dose in cervical cancer radiation therapy.

Conditions: Uterine Cervical Neoplasms

Summary: this study is an exploratory study based on the previous study " a prospective, multicenter, randomized, parallel arm-controlled, superiority clinical study to evaluate the role of hydrogel spacer in reducing rectal radiation dose in cervical cancer radiation therapy", in which additional follow up study on the subjects of the previous study were conducted. subjects (6 subjects in phase i; 100 subjects in phase ii, 50 in the test group and 50 in the control group) who completed the pre-study will be enrolled in this study if they are willing to participate in the long-term follow-up by signing the informed consent form.

the purpose of this study is to evaluate the long-term benefit of hydrogel spacer when hydrogel is injected between the rectum and cervix in women undergoing radiation therapy.

Eligibility criteria:
inclusion criteria: * karnofsky score ≥ 70. subjects aged ≥ 18 years and ≤ 75 years. subjects must be able to cooperate in completing the entire study. the subjects' pelvic and abdominal cavity and joints are free of metal implants and can tolerate mri. no contraindications to ct scanning. subjects must be able to understand the purpose of the trial, voluntarily participate and sign an informed consent form exclusion criteria: * subjects whose target tumors have been previously treated (chemotherapy, immunotherapy, surgical treatment, etc.) subjects with other primary malignancies subjects with contraindications to radiotherapy, as determined by the investigators subjects with injection site infections. subjects who are allergic to the ingredients of the device. subjects whose tumors invade the injection site and affect the injection process and injection safety, as determined by the investigators persons with severe mental illness, cognitive impairment and thinking disorders. participants in other drug clinical trials or medical device clinical trials 1 month prior to screening pregnant or lactating women or those who plan to get pregnant within the last six months subjects who cannot be followed up as prescribed by the doctor other conditions that, in the judgment of the investigator, make the subject unsuitable for enrollmen

Keywords: cervical cancer hydrogel spacer
effects of core exercise in low back pain

Conditions: Low Back Pain

Summary: non-specific low back pain in one of the main causes of disability for health care worldwide. the effectiveness of therapeutic exercise, of kinesio tape and of manual therapy in the treatment of low back pain is evaluated, but not a comparison of these techniques. moreover, can these techniques be combined?

non-specific low back pain is one of the main causes of disability for health care worldwide. nowadays, the mostly used technique to research low back muscular activity in electromyography. among the published studies, the effectiveness of therapeutic exercise, of kinesio tape and of manual therapy in the treatment of low back pain is evaluated, but not a comparison of these techniques. therefore, the purpose of this study was to investigate the effects of core stability exercise alone or in combination with manual therapy or kinesiotape on pain, dysfunction, psychosocial factors and pressure pain threshold (ppts) in patients with low back pain in odi stage 2. the investigators hypothesized that exercise combined with manual therapy would provide greater changes and benefits than exercise alone. this study's population will be composed by at least 15 individuals per group, both the male and female, with ages among 20 and 60. participants will be randomly and blindly divided in three groups of intervention. the three groups will be: exercise group or et (realize therapeutic exercise alone), manual therapy group o etmanualtherapy (realize manual therapy prior therapeutic exercise), and kinesiotape group or etkinesiotape (realize therapeutic exercise plus kinesiotape).

Eligibility criteria:
inclusion criteria: * medical diagnosis of clbp confirmed by an orthopaedic specialist classification at stage 2 by odi not receiving pharmacological treatment such as anti-inflammatories or corticosteroids. exclusion criteria: * previous or scheduled surgeries in the low back and abdominal area * presence of severe fractures or pathologies. * diagnosis of radiculopathy or neuropathy (with or without spinal canal stenosis). * structural deformity in the spinal column. * neurological or psychiatric disorder. * presence or suspicion of pregnancy.

Keywords: chronic pain muskuloskeletal manipulation complementary therapies catastrophization kinesiophobia
dentinal hypersensitivity reduction

Conditions: Dentinal Hypersensitivity

Summary: the objective of this clinical study is to assess the efficacy of a dentifrice containing stannous fluoride (colgate-palmolive company, new york, ny, usa) as compared to a commercially-available potassium-based toothpaste (sensodyne extra whitening toothpaste, glaxosmithkline co., uk) and a commercially available non-desensitizing toothpaste (colgate cavity protection toothpaste, colgate-palmolive company, new york, ny, usa) in the reduction of dentinal hypersensitivity over a seven (7) day period.


Eligibility criteria:
inclusion criteria: * sign an informed consent form; * male or female 18 to 70 years of age, inclusive; * be in good general health as determined by the study investigators; * available for the seven (7) days duration of the study; * must present two (2) sensitive teeth which must meet all of the following criteria: * be anterior to the molars and demonstrating dentin exposure due to cervical erosion/abrasion and/or gingival recession; * have a qualifying dentin hypersensitivity response to tactile stimuli applied to the cervical surface (gingivo-facial 1/3) as defined by a response score between 10- 50grams of force (yeaple probe, xinix research inc. portsmouth, nh, usa); * have a qualifying dentin hypersensitivity response to air blast stimuli applied for one second to the cervical surface (gingivo-facial 1/3) as defined by a score of 2 or 3 on the schiff cold air sensitivity scale exclusion criteria: * gross oral pathology, chronic disease, and/or history of allergies to any of the test products; * use of a desensitizing oral care product and/or recipient of any dental desensitizing treatment within the past three months prior to start of the study; * advanced periodontal disease and/or treatment for periodontal disease (including surgery) within the past twelve months; * sensitive teeth with a mobility greater than one; * teeth with extensive/defective restorations (including prosthetic crowns), suspected pulpitis, caries, cracked enamel, or used as abutments for removable partial dentures; * current use of anticonvulsants, antihistamines, antidepressants, sedatives, tranquilizers, anti-inflammatory drugs, or daily use of analgesics; * participation in any other oral clinical study for the duration of this study * self-reported pregnancy and/or currently breastfeeding; * allergies to oral care products, personal care consumer products, and/or their ingredients; * medical condition which prohibits not eating/drinking for 4 hours.

Keywords: tactile airblast dentin hypersensitivity
renal impact of kaftrio in mucoviscidose population

Conditions: Cystic Fibrosis

Summary: the objective of this study is to describe the renal impact of elexacaftor-teacaftor-ivacaftor, a triple modulator therapy of cftr channel, in patients with cystic fibrosis. this new treatment acts on the cftr channel, which is expressed at the level of the nephrons. the objective is to study the changes in plasma and urinary parameters, including metabolic explorations of urolithiasis, change in volemic parameters, renal function, urinary sediment and nutritional and glycemic parameters, in newly treated patients, through the data collected at introduction of the treatment and during the follow-up.


Eligibility criteria:
inclusion criteria: * patient with cystic fibrosis * more than 18 years old * eligible for kaftrio exclusion criteria: * kaftrio contraindication * patient less than 18 years old * dialysis patient * pregnant woman * greffed patient * patient opposition to data collection

Keywords: cystic fibrosis kaftrio renal impact lithiasis
laparoscopic eradication of deep endometriosis with nerve-sparing rectosigmoid segmental resection (rsres_nervsp)

Conditions: Endometriosis

Summary: this is a single-center, retrospective case-control study. all consecutive women who underwent classic and nerve-sparing segmental rectosigmoid resection between january 2005 and june 2022 will be included. in the majority of cases classic segmental rectosigmoid resection was done between january 2005 and december 2010. nerve-sparing segmental rectosigmoid resection has been increasingly employed since january 2011 until now. preoperative (anamnestic, physical objective, and ultrasonographic data), surgical and postoperative data of the patients included in this study will be analyzed. in particular, postoperative data will be obtained by analyzing reports of follow-up visits, which are routinely done at our institution at 1, 6, 12 months and then every year following the surgical procedures.


Eligibility criteria:
inclusion criteria: * consecutive women who underwent classic and nerve-sparing segmental rectosigmoid resection between january 2005 and june 2022 * age more than 18 years. exclusion criteria: * diagnosis of other/concomitant preoperative and/or postoperative medical or surgical conditions altering pelvic organ function (i.e. multiple sclerosis, irritable bowel syndrome); * age \<18 years.
do therapy dogs improve behavior and reduce anxiety in pediatric dental patients?

Conditions: Therapy Animals; Dental Anxiety; Child Behavior; Anesthesia, Local

Summary: the goal of this clinical trial is to assess whether the presence of a certified therapy dog during dental procedures that require an injection reduces anxiety and improves behavior in pediatric dental patients. the main questions it aims to answer are: * does the presence of a certified therapy dog during dental procedure requiring an injection reduce anxiety and improve behavior in pediatric dental patients? * how do the parents of pediatric dental patients who participate in the study view the use of a certified therapy dog in their child's treatment? * does the presence of a certified therapy dog result in different concentrations of microbes in the treatment room? all participants will receive standard of care. researchers will compare the group with a therapy dog present to a group who does not have a therapy dog present to see if heart rate, oxygen saturation, percentage of nitrous oxide administered, and frankl scores differ between the groups.


Eligibility criteria:
inclusion criteria: * age 3-7 * children who are patients at the medical university of south carolina department of pediatric dentistry * children classified as category 1 or 2 according to the american society of anesthesiologists physical status classification * children whose parents/guardians are willing to consent to the child participating in the study * availability of parent to be present during treatment * children who require further care that includes the injection of a local anesthetic and whose procedure will take less than one hour exclusion criteria: * patients whose cases are considered emergencies * patients who are classified as category 3 or higher according to the american society of anesthesiologists physical status classification (6) * if patient's medical status has worsened since initial evaluation * known allergy to dogs or other animals * past history of dental trauma * past history of animal bites or traumatic experience with a dog * emotional or developmental delays * if, on the day of the treatment, patient presents with fever or other illness
effect of integrated ckd care program in early diabetic nephropathy in primary health care setting.

Conditions: Chronic Kidney Disease; Diabetic Nephropathy

Summary: chronic kidney disease (ckd) is a major health problem in thailand. previous studies have demonstrated that integrated pre-dialysis care may slow the decline in renal function (nephrol dial transplant.2009 nov;24(11):3426-33). it is interesting to know whether early intervention especially in high risk groups like diabetic may also improve outcome of these patients in primary health care setting resulting in delay of ckd progression.

we conducted a 12-month longitudinal study at district a (control) and b (intervention) at kamphaeng phet province, thailand. diabetic patients with egfr ≥ 60 ml/min/1.73m2 were recruited from both districts. patients in district a (control group) received standard ckd care according to nkf-k/doqi guidelines1 whereas those in district b (intervention) received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. our home visits team consisted of nurse, health care officers and village health volunteers. during each hospital visit of both groups clinical data were assessed. all laboratory parameters were collected every 3 months, and ldl and hba1c every 6 months. the primary end point was rate of egfr decline. secondary outcomes were random urine albumin to creatinine ratio (acr), blood pressure, waist circumference, hba1c and ldl .

Eligibility criteria:
inclusion criteria: * diabetic patients with egfr are equal or more than 60 ml/min/1.73m2 estimated twice at 3 months. exclusion criteria: * active glomerular disease, obstructive uropathy, end-stage renal disease, hiv infection, pregnancy, body mass index (bmi) less than 18 or more than 40 kg/m2, being under treatment for malignancy, urine protein-creatinine ratio more than 3.5 g/g creatinine and active urinary sediment (urine red blood cells \>3 cells/high power field or urine white blood cells \>10 cells/high power field).

Keywords: chronic kidney disease diabetic nephropathy integrated chronic kidney disease care
a study of multiple immunotherapy-based treatment combinations in participants with metastatic pancreatic ductal adenocarcinoma (morpheus-pancreatic cancer)

Conditions: Pancreatic Adenocarcinoma

Summary: a phase ib/ii, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic pancreatic ductal adenocarcinoma (pdac). two cohorts will be enrolled in parallel in this study: cohort 1 will consist of patients who have received no prior systemic therapy for metastatic pdac, and cohort 2 will consist of patients who have received one line of prior systemic therapy for pdac. in each cohort, eligible patients will be assigned to one of several treatment arms.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0 or 1 * histologically or cytologically confirmed metastatic pancreatic ductal adenocarcinoma * for patients in cohort 1: no prior systemic treatment for pdac * for patients in cohort 2: disease progression during administration of either 5-fu- or gemcitabine-based first-line chemotherapy * life expectancy greater than or equal to 3 months * availability of a representative tumor specimen that is suitable for determination of programmed death-ligand 1 (pd-l1) and/or additional biomarker status via central testing * measurable disease (at least one target lesion) according to recist v1.1 * adequate hematologic and end-organ function test results * tumor accessible for biopsy * for women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating eggs, as outlined for each specific treatment arm * for men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm exclusion criteria: * uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage procedure (i.e., more than one time per month) * symptomatic, untreated, or actively progressing central nervous system (cns) metastases * history of leptomeningeal disease * active or history of autoimmune disease or immune deficiency * history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (ct) scan * positive human immunodeficiency (hiv) test at screening or at any time prior to screening * active hepatitis b or c virus infection or active tuberculosis * severe infection within 4 weeks prior to initiation of study treatment * prior allogeneic stem cell or solid organ transplantation * history of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death